Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23,746 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models.
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Han L, et al. Among authors: kim e. Haematologica. 2020 Mar;105(3):697-707. doi: 10.3324/haematol.2018.205534. Epub 2019 May 23. Haematologica. 2020. PMID: 31123034 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 31727768
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study.
Bolen CR, Klanova M, Trneny M, Sehn LH, He J, Tong J, Paulson JN, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard MZ. Bolen CR, et al. Among authors: kim e. Haematologica. 2020 Sep 1;105(9):2298-2307. doi: 10.3324/haematol.2019.227892. Haematologica. 2020. PMID: 33054054 Free PMC article.
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Punnoose E, Peale FV, Szafer-Glusman E, Lei G, Bourgon R, Do AD, Kim E, Zhang L, Farinha P, Gascoyne RD, Munoz FJ, Martelli M, Mottok A, Salles GA, Sehn LH, Seymour JF, Trnĕný M, Oestergaard MZ, Mundt KE, Vitolo U. Punnoose E, et al. Among authors: kim e. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):267-278.e10. doi: 10.1016/j.clml.2020.11.004. Epub 2020 Nov 10. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33303421 Free article.
A myeloid program associated with COVID-19 severity is decreased by therapeutic blockade of IL-6 signaling.
Hackney JA, Shivram H, Vander Heiden J, Overall C, Orozco L, Gao X, Kim E, West N, Qamra A, Chang D, Chakrabarti A, Choy DF, Combes AJ, Courau T, Fragiadakis GK, Rao AA, Ray A, Tsui J, Hu K, Kuhn NF, Krummel MF, Erle DJ, Kangelaris K, Sarma A, Lyon Z, Calfee CS, Woodruff PG, Ghale R, Mick E, Byrne A, Zha BS, Langelier C, Hendrickson CM, van der Wijst MGP, Hartoularos GC, Grant T, Bueno R, Lee DS, Greenland JR, Sun Y, Perez R, Ogorodnikov A, Ward A, Ye CJ; UCSF COMET Consortium; Ramalingam T, McBride JM, Cai F, Teterina A, Bao M, Tsai L, Rosas IO, Regev A, Kapadia SB, Bauer RN, Rosenberger CM. Hackney JA, et al. Among authors: kim e. iScience. 2023 Sep 1;26(10):107813. doi: 10.1016/j.isci.2023.107813. eCollection 2023 Oct 20. iScience. 2023. PMID: 37810211 Free PMC article.
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
West HJ, McCleland M, Cappuzzo F, Reck M, Mok TS, Jotte RM, Nishio M, Kim E, Morris S, Zou W, Shames D, Das Thakur M, Shankar G, Socinski MA. West HJ, et al. Among authors: kim e. J Immunother Cancer. 2022 Feb;10(2):e003027. doi: 10.1136/jitc-2021-003027. J Immunother Cancer. 2022. PMID: 35190375 Free PMC article. Clinical Trial.
23,746 results
You have reached the last available page of results. Please see the User Guide for more information.